- Home
- BLIN vs INAB Comparison
BLIN vs INAB Comparison
Compare BLIN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLIN | INAB |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 10.6M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLIN | INAB |
|---|---|---|
| Price | $0.99 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.62 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 79.6K | 52.2K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,375,000.00 | N/A |
| Revenue This Year | $2.68 | N/A |
| Revenue Next Year | $16.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.54 | N/A |
| 52 Week Low | $0.90 | $1.53 |
| 52 Week High | $2.80 | $12.53 |
Technical Indicators
Market Signals| Indicator | BLIN | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 37.58 |
| Support Level | $0.98 | $1.73 |
| Resistance Level | $1.12 | $1.87 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 31.53 | 0.00 |
Price Performance
Historical ComparisonAbout BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.